PPCB
Propanc Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · AU
$1.01
−0.98%Aug 18, 2026, 12:30 UTC
Propanc Biopharma announced it has commenced finalization of a clinical trial protocol and will conduct a feasibility assessment for its First-In-Human Phase 1b clinical study of PRP in up to 40 advanced cancer patients with solid tumors.
Source:Aug 6, 2026, 12:30 UTC
Propanc Biopharma announced positive preclinical and early translational data for its lead candidate PRP in pancreatic ductal adenocarcinoma models, showing over 90% tumor growth inhibition and significant survival benefit.
Aug 5, 2026, 12:30 UTC
Propanc Biopharma announced the completion of the first tranche of $500,000 of its $5.0 million share repurchase program within the first 30 days since commencing the program.
Source:Jul 7, 2026, 12:30 UTC
Propanc Biopharma signed a Memorandum of Understanding with Avance Clinical Pty Ltd to collaborate on the clinical delivery of Propanc's Phase 1b trial for PRP.
Source:Jun 11, 2026, 12:30 UTC
Propanc Biopharma authorized a share repurchase program of up to $5.0 million of its common stock.